ALDH1A3 has been shown to correlate with poor patient survival, disease progression, and recurrence in many cancers, including breast, prostate, glioblastoma, neuroblastoma, pancreatic, gastric, gall bladder, colon, and intrahepatic cholangiocarcinoma cancers [2, 3, 14, 43, 44, 45, 46, 47, 48, 49]. Here, ALDH1A3 is linked to neuroblastoma.